Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. boosted its position in Sana Biotechnology, Inc. (NASDAQ:SANA) by 286.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 197,386 shares of the company’s stock after acquiring an additional 146,303 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned 0.10% of Sana Biotechnology worth $805,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Jump Financial LLC acquired a new position in Sana Biotechnology in the third quarter valued at $52,000. China Universal Asset Management Co. Ltd. boosted its holdings in Sana Biotechnology by 351.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,800 shares of the company’s stock valued at $93,000 after acquiring an additional 17,753 shares during the last quarter. SG Americas Securities LLC acquired a new position in Sana Biotechnology in the fourth quarter valued at $99,000. Arizona State Retirement System boosted its holdings in Sana Biotechnology by 12.2% in the fourth quarter. Arizona State Retirement System now owns 27,527 shares of the company’s stock valued at $112,000 after acquiring an additional 2,991 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in Sana Biotechnology by 13.1% in the third quarter. Principal Financial Group Inc. now owns 42,664 shares of the company’s stock valued at $165,000 after purchasing an additional 4,928 shares during the period. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Stock Performance

Shares of NASDAQ SANA opened at $8.58 on Thursday. Sana Biotechnology, Inc. has a 1 year low of $2.74 and a 1 year high of $12.00. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of -5.84 and a beta of 1.61. The stock’s 50-day simple moving average is $9.07 and its 200-day simple moving average is $6.05.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Thursday, February 29th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.03. During the same period in the previous year, the business earned ($0.40) EPS. As a group, research analysts predict that Sana Biotechnology, Inc. will post -1.02 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. JMP Securities raised their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the company a “market outperform” rating in a research report on Friday, March 1st. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Sana Biotechnology in a research report on Friday, March 1st.

Insider Transactions at Sana Biotechnology

In other news, Director Robert Nelsen acquired 1,818,181 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was purchased at an average cost of $5.50 per share, with a total value of $9,999,995.50. Following the completion of the acquisition, the director now directly owns 12,446,022 shares in the company, valued at $68,453,121. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 34.90% of the company’s stock.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.